Arjen M. Rijken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arjen M. Rijken has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Antonia M van Leeuwen
Department of Pathology, Rijnland Hospital, Leiderdorp, the Netherlands
1 shared publication - C. Al Ali
Department of Surgery, Amphia Hospital, PO Box 90157, 4800 RL Breda, The Netherlands
1 shared publication - Coriene J. L. M. Catsman
Department of Surgery, Amphia Hospital, Molengracht 21, 4818, CK, Breda, The Netherlands
1 shared publication D. J. de Gooyer
Department of Oncology, Bravis Hospital, Roosendaal/Bergen op Zoom, Netherlands
1 shared publication- F Jeroen Vogelaar
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
1 shared publication F. Imani
Department of Radiology, Amphia Hospital, Breda, Netherlands
1 shared publication
Latest Publications
- Open Access
- 3 April 2021
- Published by Hindawi Limited in Case Reports in Surgery
- Vol. 2021, 1-4
Appearance of Focal Nodular Hyperplasia after Chemotherapy in Two Patients during Follow-Up of Colon Carcinoma
Surgical liver resection is a treatment option in patients with resectable colorectal liver metastases. We present two cases of focal nodular hyperplasia (FNH) development after treatment with oxaliplatin during follow-up of colon carcinoma. The first case was a 40-year-old male patient who developed multiple liver lesions suspect for metastatic disease four years after he had undergone laparoscopic right-sided hemicolectomy and adjuvant chemotherapy (capecitabine and oxaliplatin). He underwent a metastasectomy of segments three and four and microwave ablation (MWA) of the lesion in segment one. Pathological analysis demonstrated FNH. The second patient was a 21-year-old woman who presented with multiple liver lesions during follow-up for colon carcinoma. She underwent a laparoscopic right-sided hemicolectomy and was adjuvantly treated with capecitabine and oxaliplatin three years ago. Magnetic resonance imaging (MRI) was performed, and the lesions showed no signs of metastatic disease but were classified as FNH. Therefore, the decision was made to follow up the patient. In conclusion, the development of benign liver lesions could occur during follow-up of colon carcinoma and might be caused by oxaliplatin-induced changes to the liver parenchyma. Hence, it is important to distinguish these from metastatic liver disease.
- 3 April 2021
- Published by Hindawi Limited in Case Reports in Surgery
- Vol. 2021, 1-4
Open AccessAppearance of Focal Nodular Hyperplasia after Chemotherapy in Two Patients during Follow-Up of Colon Carcinoma
Surgical liver resection is a treatment option in patients with resectable colorectal liver metastases. We present two cases of focal nodular hyperplasia (FNH) development after treatment with oxaliplatin during follow-up of colon carcinoma. The first case was a 40-year-old male patient who developed multiple liver lesions suspect for metastatic disease four years after he had undergone laparoscopic right-sided hemicolectomy and adjuvant chemotherapy (capecitabine and oxaliplatin). He underwent a metastasectomy of segments three and four and microwave ablation (MWA) of the lesion in segment one. Pathological analysis demonstrated FNH. The second patient was a 21-year-old woman who presented with multiple liver lesions during follow-up for colon carcinoma. She underwent a laparoscopic right-sided hemicolectomy and was adjuvantly treated with capecitabine and oxaliplatin three years ago. Magnetic resonance imaging (MRI) was performed, and the lesions showed no signs of metastatic disease but were classified as FNH. Therefore, the decision was made to follow up the patient. In conclusion, the development of benign liver lesions could occur during follow-up of colon carcinoma and might be caused by oxaliplatin-induced changes to the liver parenchyma. Hence, it is important to distinguish these from metastatic liver disease.
- Open Access
- 4 January 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 1-3
Talc seromadesis in patients with chronic seroma formation after breast surgery
Seroma formation, after breast surgery is a commonly seen complication with an incidence ranging from 10 to 85 %. In general, though seroma usually disappears within several weeks, some patients are troubled with chronic seroma. Seroma predisposes to infection leading to wound related complications and may also delay adjuvant chemoradiation, leading to less effective breast cancer treatment. A 52-years-old Dutch woman presenting with a pT3N1M0 infiltrating lobular breast carcinoma received neo-adjuvant chemotherapy, following modified radical mastectomy with sentinel node procedure. She suffered from chronic seroma formation, delaying adjuvant radiation therapy. We successfully performed talc seromadesis to eliminate seroma formation. During six-month follow-up, no seroma was detected. Talc seromadesis after breast surgery is a rarely described in literature. In order to develop this technique further research aimed to evaluate its effectiveness on safety and possible later breast reconstruction must be carried out. Talc seromadesis may be a safe, cost effective and minimally invasive solution to treat chronic seroma after breast surgery.
- 4 January 2016
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 1-3
Open AccessTalc seromadesis in patients with chronic seroma formation after breast surgery
Seroma formation, after breast surgery is a commonly seen complication with an incidence ranging from 10 to 85 %. In general, though seroma usually disappears within several weeks, some patients are troubled with chronic seroma. Seroma predisposes to infection leading to wound related complications and may also delay adjuvant chemoradiation, leading to less effective breast cancer treatment. A 52-years-old Dutch woman presenting with a pT3N1M0 infiltrating lobular breast carcinoma received neo-adjuvant chemotherapy, following modified radical mastectomy with sentinel node procedure. She suffered from chronic seroma formation, delaying adjuvant radiation therapy. We successfully performed talc seromadesis to eliminate seroma formation. During six-month follow-up, no seroma was detected. Talc seromadesis after breast surgery is a rarely described in literature. In order to develop this technique further research aimed to evaluate its effectiveness on safety and possible later breast reconstruction must be carried out. Talc seromadesis may be a safe, cost effective and minimally invasive solution to treat chronic seroma after breast surgery.
- 1 September 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (9) , 1217-1225
Large variation in the utilization of liver resections in stage IV colorectal cancer patients with metastases confined to the liver
- 1 September 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (9) , 1217-1225
Large variation in the utilization of liver resections in stage IV colorectal cancer patients with metastases confined to the liver
- Open Access
- 20 April 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 153
Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study
Large number of patients with colorectal liver metastasis show recurrent disease after curative surgical resection. Identification of these high-risk patients may guide therapeutic strategies. The aim of this study was to evaluate whether the presence of disseminated tumor cells in bone marrow from patients undergoing surgical resection of colorectal liver metastases can predict clinical outcome.
- 20 April 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 153
Open AccessClinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study
Large number of patients with colorectal liver metastasis show recurrent disease after curative surgical resection. Identification of these high-risk patients may guide therapeutic strategies. The aim of this study was to evaluate whether the presence of disseminated tumor cells in bone marrow from patients undergoing surgical resection of colorectal liver metastases can predict clinical outcome.